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centuries. Recently, scientific and epidemiologic research has focused 
on its content in flavonoids and its potential to promote health and/or 
reduce risk factors for various diseases. Chocolate is also an energy-
rich food item. As such, it may promote positive energy balance, body 
weight gain, and ultimately become a risk for public health. Chemical 
compounds found in cocoa are fragile. During the multiple processes 
of chocolate production, these compounds may be degraded. In addi-
tion, adjunctions to cocoa to generate specific chocolate brands may 
have positive or negative biological of the final product. The art of the 
chocolate maker is to protect the cocoa values during the chocolate 
production and to select additives having interesting organoleptic 
values and positive health properties.
Conclusion: Many associations between chocolate consumption, 
health, and diseases are proven. The complexity of the cocoa com-
pounds warrants further investigations to substantiate the benefits/
disadvantages of chocolate, and to identify if chocolate should remain 
a food for pleasure and/or dietary supplement.
Learning objectives: Identify the chocolate’s properties. Learn the 
main hypotheses addressing the chocolate’s health-promoting values. 
Discover the relationship between chocolate, health, and diseases. 
Understand the differences between industrial and artisanal pro-
cesses, and their impact on the final product.
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Medication use: FroM leaFlet to 
elearning
V. Piguet*
Clinical Pharmacology and Toxicology, Geneva University 
Hospitals, Geneva, Switzerland
Summary: Medication adherence is poor, especially for chronic dis-
eases, leading to reduced treatment effectiveness and increased health 
care costs. As defined by WHO, “adherence is a multidimensional 
phenomenon determined by the interplay of five dimensions of which 
patient-related factors are just one determinant.” One of the differ-
ent ways to improve adherence is to enhance patients’ knowledge 
about medication that implies taking into account patients’ experi-
ences, expectations, and beliefs about medication efficacy and adverse 
effect in the context of their illness. Patient information leaflets (PIL), 
legally required by many countries, provide comprehensive informa-
tion, but they are not necessarily related to patients’ level of literacy 
nor do they answer individual situations. The Internet is more and 
more used as a source for health information. Patients report that 
this media allows them to get second opinions, cross-checking, and 
more tailored information through experience sharing. However, they 
could also be deceived, confused, or frightened by what they are 
finding on some Web sites or forums. ELearning programs based on 
constructivist learning theories are aiming, through self-involvement 
and interactivity, at improving patients’ knowledge and skills to use 
medicine in a safer way.
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the Makings oF the world-class athlete: 
physiologic, genetic, psychosocial and 
econoMic deterMinants
Y. Pitsiladis*
College of Medicine, Veterinary & Life Sciences, Institute of 
Cardiovascular & Medical Sciences, University of Glasgow, 
Glasgow, United Kingdom
Summary: A look at the final medal tally at the XXX Olympiad in 
London reveals that certain nations enjoy particular success on the 
running track and the marathon. Compelling examples are that of east 
African athletes from Kenya and Ethiopia, with their domination of 
middle- and long-distance running, and that of athletes from Jamaica 
and the United States, with their domination of sprint events. The 
London results have undoubtedly enhanced the concept that certain 
ethnic groups possess some inherent genetic advantage predisposing 
them to superior athletic performance. However, there is no genetic 
evidence to suggest that this is the case, although research is ongoing 
and predominantly implicates environmental factors. Genetic studies 
of elite distance runners from Kenya and Ethiopia and elite sprinters 
from Jamaica, the United States, and Nigeria do not find that these 
athletes possess a unique genetic makeup; rather they serve to high-
light the high degree of genetic diversity among ethnic groups. It is 
unjustified, therefore, to regard ethnic differences in sporting success 
as genetically mediated; to justify doing so one must identify the genes 
that are important, which until now has proven elusive.
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developMent oF partnerships between 
the biopharMaceutical industry and  
the world anti-doping agency
O. Rabin*
World Anti-Doping Agency, Lausanne, Switzerland
Summary: Recent cases of doping in elite sports have shown that 
drugs in development have been misappropriated during clinical tri-
als and supplied to athletes or members of their entourage with a 
view to being used for performance-enhancing purposes. Certain 
innovative drugs, in particular those with chemical structures simi-
lar to endogenous substances, are especially difficult to detect. It 
requires substantial time and investment by antidoping authorities 
to develop detection methods that can then be integrated into the 
routine antidoping analysis of WADA-accredited laboratories. In a 
bid to facilitate detection methods for drugs in development that have 
doping potential, WADA has created partnerships and engaged in 
collaboration with pharmaceutical and biotechnology companies, as 
well as with the related biopharmaceutical associations. The ration-
ale is to bring about an exchange of information before these drugs 
have completed their clinical development and become commercially 
available. This exchange of information has already proven to be of 
great value to the antidoping authorities, while it has also allowed 
the pharmaceutical and biotechnology companies to benefit from 
WADA’s experience in the risk-management of their substances in 
development and the possibility of counterfeiting by illegal laborato-
ries and unscrupulous companies. This approach continues to expand 
as more companies embrace the collaborative model. The ultimate 
aim always will be to deter and prevent athletes from abusing these 
drugs, because such abuse poses a very real risk to their health and 
continues to be a major threat to clean athletes and clean sport.
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the role oF the clinical pharMacologist 
in pharMacoeconoMics/health 
econoMics
M. Rawlins*
Royal Society of Medicine, London, United Kingdom
Summary: Clinical pharmacologists should be playing a much larger 
role in the economic evaluation of medicines than hitherto. They have 
particular expertise in: choice of comparator interventions; appraisal 
of study designs of clinical effectiveness; appropriateness of post hoc 
subgroups; generalizability (external validity) of the pivotal studies; 
and inputs into, and face validity of, economic models.
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targets For drug developMent  
in hiv neuropathy
A.S.C. Rice*
Pain Research, Imperial College, London, United Kingdom
Summary: There are globally ~34 million people infected with HIV. 
About 40% of those people living with HIV, whose infection is sup-
pressed by antiretroviral therapy (ART) and are often otherwise well, 
have a length-dependent distal symmetrical sensory polyneuropathy, 
which in most cases is associated with neuropathic pain. This makes 
sensory neuropathy 1 of the most prevalent clinical manifestations 
of HIV in the current era of combined ART and therefore an increas-
ingly major area of therapeutic need. Sensory neuropathy is usu-
ally attributable to either viral–neuronal interactions and/or ART 
neurotoxicity.
Data will be reviewed for:
-  the epidemiologic and risk factors of HIV-associated neuropathy
-  efficacy of current therapies: a meta-analysis of current rand-
omized controlled trials for neuropathic pain in HIV
-  sensory profiles and other clinical characteristics in HIV-positive 
patients with and without sensory neuropathy
-  laboratory animal modeling of HIV GP120-induced neuropa-
thy, including ethologically relevant complex pain behaviors and 
pharmacologic analysis
-  laboratory animal modeling of ART neurotoxicity, including 
ethologically relevant complex pain behaviors and pharmaco-
logic analysis
-  use of gene microarray studies of animals models to reveal novel 
drug targets
Disclosure of Interest: A. Rice: shareholder of Spinifex; grant/
research support from Pfizer and Astellas; consultant for Imperial 
College; consultants for in last 12 months Spinifex and Astellas; and 
other: PI in IMI-EUROPAIN.
update on the status oF arteMisinin 
resistance
P. Ringwald*
World Health Organization, Geneva, Switzerland
Summary: Drug Resistance and Containment Unit, Global Malaria 
Programme, World Health Organization, Geneva, Switzerland.
Global malaria control has been threatened by resistance to 
antimalarial medicines. P falciparum resistance to chloroquine and 
pyrimethamine both originated in Southeast Asia and subsequently 
spread to Africa with substantial implications for global public health. 
Similarly, in the 1980s, resistance to mefloquine emerged rapidly on 
the western border of Cambodia and on the northwest border of 
Thailand only a few years after its introduction. In April 2001, WHO 
recommended the use of artemisinin-based combination therapies 
(ACTs), combining an artemisinin derivative, known for its rapid 
action and short elimination from the body, with another drug char-
acterized by a different mechanism of action and slow elimination.
Emerging P falciparum resistance to artemisinin derivatives is 
a major global public health concern. WHO first issued a warning 
about the threat of artemisinin resistance in the Greater Mekong sub-
region in 2005, after routine efficacy studies showed delayed clear-
ance after ACTs. The first cases of confirmed artemisinin resistance 
were found in western Cambodia, along the Cambodia–Thailand 
border in late 2006. The 4 countries most affected by the emergence 
of artemisinin resistance are Cambodia, Myanmar, Thailand, and 
Vietnam. Despite observed changes in parasite sensitivity to arte-
misinins, ACTs continue to cure patients, provided the partner drug 
is efficacious. However, once resistance to artemisinin emerges, it is 
more likely that resistance to the partner drug will also develop and 
vice versa. Currently and in absence of a molecular marker, the best 
available indicator of suspected artemisinin resistance is the propor-
tion of patients who are still parasitemic at day 3 (72 hours) after a 
full course of an ACT.
In 2010, WHO developed the Global Plan for Artemisinin 
Resistance Containment (GPARC). The plan was drafted after a con-
sultation with all constituencies of the Roll Back Malaria Partnership, 
as well as a range of donor organizations and industry partners. 
WHO is also currently implementing an emergency response plan 
to scale-up efforts to contain artemisinin resistance in the Greater 
Mekong subregion. The presentation will provide an update of the 
current status of artemsinin resistance and containment activities.
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undergraduate training For Medical 
students in cpt and prescribing
S. Ross*
Division of Medical and Dental Education, University of 
Aberdeen Aberdeen, Aberdeen, United Kingdom
Summary: Prescribing is a complex task and is often undertaken 
by the most inexperienced doctors. From day 1, new doctors need 
to be able to prescribe safely and rationally. It is clear that this 
requires more than traditional textbook knowledge of pharmacology. 
Preparing new graduates to be effective prescribers is 1 of the major 
concerns of modern undergraduate medical education. Evidence sug-
gests that this training could be improved, although there is debate 
about the most effective methods for doing so.
This presentation will review the perceived deficiencies of current 
teaching, the challenges of delivering effective prescribing education, 
and the available evidence on a range of teaching and learning meth-
ods. In particular, the UK British Pharmacological Society 2012 rec-
ommendations for undergraduate education in clinical pharmacology 
and therapeutics will be used as an example of how medical educators 
might approach this difficult area.
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coMplexity oF predicting the Magnitude 
oF drug-drug interactions in an 
individual patient: this cannot Fit to a 
pocket guide; ipad May be!
A. Rostami-Hodjegan*
School of Pharmacy and Pharmaceutical Sciences, University of 
Manchester, Manchester, United Kingdom
Summary: The increased prominence of in vitro–in vivo extrapola-
tion (IVIVE) capabilities has helped with recognizing the potential of 
drug–drug interactions (DDI) at early stages of drug discovery. Latest 
regulatory guidelines by the EMA and FDA provide recommenda-
tions for conduct of IVIVE through modeling. They are designed to 
protect the public from adverse effects associated with likely DDI 
by appropriate labeling or preventing the marketing of drugs with 
unmanageable DDI. However, DDI in an individual patient are deter-
mined by a myriad of variables. Prescribers may use labels in the 
clinical practice; nonetheless, currently, labels do not provide infor-
mation for all the different permutation of conditions that put certain 
subgroup of patients at higher risk (eg, comorbid diseases, genetics, 
age and intake of several drugs). Some recent attempts by both the 
FDA and EMA have moved the focus from an average individual to 
a perceived susceptible patient (eg, chronic renal failure).
Creation of user-friendly interface computer programs of DDI 
prediction, which takes the sources of variability into account, may 
assist with the prediction and management of DDI in an individual 
patient. The required information on drugs (ie, affinity to various 
enzymes, nonenzymatic routes, permeability, protein binding, inhibi-
